PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32292906-10 2020 We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease. resiniferatoxin 46-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 85-90 32292906-10 2020 We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease. resiniferatoxin 46-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 196-201 32292906-10 2020 We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease. resiniferatoxin 63-66 transient receptor potential cation channel subfamily V member 1 Homo sapiens 85-90 32292906-10 2020 We also propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease. resiniferatoxin 63-66 transient receptor potential cation channel subfamily V member 1 Homo sapiens 196-201 31757360-2 2020 TRPV1 can be activated by low extracellular pH, high temperature, or naturally occurring pungent molecules such as allicin, capsaicin, or resiniferatoxin. resiniferatoxin 138-153 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 31846438-5 2020 Using epicardial Resiniferatoxin (RTX) to deplete cardiac TRPV1-expressing fibers, we dissected the role of this neural circuit in VAs after chronic MI in a porcine model. resiniferatoxin 34-37 transient receptor potential cation channel subfamily V member 1 Homo sapiens 58-63 31846438-7 2020 Epicardial RTX depleted cardiac TRPV1 afferent fibers and abolished functional responses to TRPV1 agonists. resiniferatoxin 11-14 transient receptor potential cation channel subfamily V member 1 Homo sapiens 32-37 31846438-7 2020 Epicardial RTX depleted cardiac TRPV1 afferent fibers and abolished functional responses to TRPV1 agonists. resiniferatoxin 11-14 transient receptor potential cation channel subfamily V member 1 Homo sapiens 92-97 29452097-8 2018 Stimulation of TRPV1 channels induced an influx of Ca2+ into the cells and this rise in intracellular Ca2+ was essential for activating AP-1 in capsaicin or resiniferatoxin-stimulated cells. resiniferatoxin 157-172 transient receptor potential cation channel subfamily V member 1 Homo sapiens 15-20 31399015-5 2019 Expert opinion: The therapeutic effect of TRPV1 channel desensitizing agonists (capsaicin, resiniferatoxin, given intravesically) has been convincingly demonstrated in some forms of bladder overactivity. resiniferatoxin 91-106 transient receptor potential cation channel subfamily V member 1 Homo sapiens 42-47 30644819-3 2019 It was recently discovered that four mutations in TRPV2 are sufficient to render the channel sensitive to the TRPV1-specific vanilloid agonist resiniferatoxin (RTx). resiniferatoxin 143-158 transient receptor potential cation channel subfamily V member 1 Homo sapiens 110-115 30644819-3 2019 It was recently discovered that four mutations in TRPV2 are sufficient to render the channel sensitive to the TRPV1-specific vanilloid agonist resiniferatoxin (RTx). resiniferatoxin 160-163 transient receptor potential cation channel subfamily V member 1 Homo sapiens 110-115 31263706-6 2019 TRPV1 can be activated by a large array of physical (heat, mechanical stimuli) and chemical factors (e.g., protons, capsaicin, resiniferatoxin, and endogenous ligands, such as endovanilloids). resiniferatoxin 127-142 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 30761069-6 2019 Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX). resiniferatoxin 103-118 transient receptor potential cation channel subfamily V member 1 Homo sapiens 42-47 30761069-6 2019 Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX). resiniferatoxin 103-118 transient receptor potential cation channel subfamily V member 1 Homo sapiens 84-89 30761069-6 2019 Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX). resiniferatoxin 103-118 transient receptor potential cation channel subfamily V member 1 Homo sapiens 84-89 30761069-6 2019 Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX). resiniferatoxin 120-123 transient receptor potential cation channel subfamily V member 1 Homo sapiens 42-47 30761069-6 2019 Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX). resiniferatoxin 120-123 transient receptor potential cation channel subfamily V member 1 Homo sapiens 84-89 30761069-6 2019 Moreover, the anti-inflammatory effect of TRPV1 activation was confirmed by another TRPV1 agonist, the resiniferatoxin (RTX), whose effects were significantly inhibited by the TRPV1 antagonist, 5-iodoresiniferatoxin (5-IRTX). resiniferatoxin 120-123 transient receptor potential cation channel subfamily V member 1 Homo sapiens 84-89 29746471-7 2018 We previously showed that although schistosomes contain no genes predicted to encode TRPV channels, TRPV1-selective activators such as capsaicin and resiniferatoxin elicit dramatic hyperactivity in adult worms and schistosomula. resiniferatoxin 149-164 transient receptor potential cation channel subfamily V member 1 Homo sapiens 100-105 29129206-5 2017 While activation of TRPV1 by the vanilloids capsaicin, resiniferatoxin and anandamide results in calcium-dependent cell death, activation by protons and the oxidant chloramine-T failed to reduce cell viability. resiniferatoxin 55-70 transient receptor potential cation channel subfamily V member 1 Homo sapiens 20-25 29553496-4 2018 This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy. resiniferatoxin 130-145 transient receptor potential cation channel subfamily V member 1 Homo sapiens 179-224 29553496-4 2018 This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy. resiniferatoxin 130-145 transient receptor potential cation channel subfamily V member 1 Homo sapiens 226-231 29553496-4 2018 This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy. resiniferatoxin 147-150 transient receptor potential cation channel subfamily V member 1 Homo sapiens 179-224 29553496-4 2018 This protocol describes an experimental model of small fiber neuropathy specifically affecting small-diameter sensory nerves with resiniferatoxin (RTX), an ultrapotent agonist of transient receptor potential vanilloid type 1 (TRPV1), through a single dose of intraperitoneal injection, referred to as RTX neuropathy. resiniferatoxin 147-150 transient receptor potential cation channel subfamily V member 1 Homo sapiens 226-231 28945920-7 2017 The TRPV1-specific agonists capsaicin and resiniferatoxin did not affect the intracellular Ca2+ concentration. resiniferatoxin 42-57 transient receptor potential cation channel subfamily V member 1 Homo sapiens 4-9 27976413-2 2017 TRPV1 receptors function as homotetramers responsive to heat, proinflammatory substances, lipoxygenase products, resiniferatoxin, endocannabinoids, protons, and peptide toxins. resiniferatoxin 113-128 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 29041773-1 2017 Resiniferatoxin (1) belongs to a daphnane diterpenoid family and has strong agonistic effects on TRPV1, a transducer of noxious temperature and chemical stimuli. resiniferatoxin 0-15 transient receptor potential cation channel subfamily V member 1 Homo sapiens 97-102 28892388-2 2017 While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1. resiniferatoxin 19-34 transient receptor potential cation channel subfamily V member 1 Homo sapiens 115-120 28892388-2 2017 While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1. resiniferatoxin 36-39 transient receptor potential cation channel subfamily V member 1 Homo sapiens 115-120 27606946-2 2016 Since the precise structure of TRPV1 was obtained by electron cryo-microscopy, the binding mode of representative agonists such as capsaicin and resiniferatoxin (RTX) has been extensively characterized; however, detailed information on the binding mode of other vanilloids remains lacking. resiniferatoxin 145-160 transient receptor potential cation channel subfamily V member 1 Homo sapiens 31-36 28626428-7 2017 One intrathecal resiniferatoxin (RTX) dose allows for the receptor-mediated removal of TRPV1+ neurons from the peripheral nervous system. resiniferatoxin 16-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 87-92 28626428-7 2017 One intrathecal resiniferatoxin (RTX) dose allows for the receptor-mediated removal of TRPV1+ neurons from the peripheral nervous system. resiniferatoxin 33-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 87-92 26482371-5 2016 In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons. resiniferatoxin 32-47 transient receptor potential cation channel subfamily V member 1 Homo sapiens 18-23 26482371-5 2016 In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons. resiniferatoxin 49-52 transient receptor potential cation channel subfamily V member 1 Homo sapiens 18-23 26482371-5 2016 In an ultropotent TRPV1 agonist resiniferatoxin (RTX)-induced PHN-like model, RTX treatment for 6 weeks increased netrin-1 expression in dorsal horn neurons, including NK-1-positive projection neurons. resiniferatoxin 78-81 transient receptor potential cation channel subfamily V member 1 Homo sapiens 18-23 26482371-6 2016 In human neuroblastoma SH-SY5Y cells, we found that TRPV1 antagonist capsazepine antagonized RTX-induced upregulation of netrin-1. resiniferatoxin 93-96 transient receptor potential cation channel subfamily V member 1 Homo sapiens 52-57 26482371-9 2016 Our results suggest that RTX treatment upregulates netrin-1 expression through activation of TRPV1 receptors and change UNC5H2-rich spinal dorsal horn into a growth-permissive environment by increasing DCC expression, thus enhancing the sprouting of myelinated afferent nerves. resiniferatoxin 25-28 transient receptor potential cation channel subfamily V member 1 Homo sapiens 93-98 27606946-2 2016 Since the precise structure of TRPV1 was obtained by electron cryo-microscopy, the binding mode of representative agonists such as capsaicin and resiniferatoxin (RTX) has been extensively characterized; however, detailed information on the binding mode of other vanilloids remains lacking. resiniferatoxin 162-165 transient receptor potential cation channel subfamily V member 1 Homo sapiens 31-36 27339229-2 2016 Our results have demonstrated that capsaicin and resiniferatoxin form nanomolar complexes with calmodulin, and competitively inhibit TRPV1-calmodulin interaction. resiniferatoxin 49-64 transient receptor potential cation channel subfamily V member 1 Homo sapiens 133-138 27563913-1 2016 Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). resiniferatoxin 172-187 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-40 27563913-1 2016 Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). resiniferatoxin 172-187 transient receptor potential cation channel subfamily V member 1 Homo sapiens 42-47 27563913-1 2016 Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). resiniferatoxin 189-192 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-40 27563913-1 2016 Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). resiniferatoxin 189-192 transient receptor potential cation channel subfamily V member 1 Homo sapiens 42-47 27529257-5 2016 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population. resiniferatoxin 43-58 transient receptor potential cation channel subfamily V member 1 Homo sapiens 29-34 27529257-5 2016 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population. resiniferatoxin 43-58 transient receptor potential cation channel subfamily V member 1 Homo sapiens 166-171 27529257-5 2016 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population. resiniferatoxin 60-63 transient receptor potential cation channel subfamily V member 1 Homo sapiens 29-34 27529257-5 2016 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya or nerve terminals induces calcium cytotoxicity and selective lesioning of the TRPV1-expressing nociceptive primary afferent population. resiniferatoxin 60-63 transient receptor potential cation channel subfamily V member 1 Homo sapiens 166-171 27180305-1 2016 Vanilloids including capsaicin and resiniferatoxin are potent transient receptor potential vanilloid type 1 (TRPV1) agonists. resiniferatoxin 35-50 transient receptor potential cation channel subfamily V member 1 Homo sapiens 62-107 27180305-1 2016 Vanilloids including capsaicin and resiniferatoxin are potent transient receptor potential vanilloid type 1 (TRPV1) agonists. resiniferatoxin 35-50 transient receptor potential cation channel subfamily V member 1 Homo sapiens 109-114 25903376-5 2015 We also demonstrate that TRPV1- and TRPV4-specific agonists, namely resiniferatoxin and 4alpha-phorbol-12,13-didecanoate, can cause Ca(2+) influx in T cells. resiniferatoxin 68-83 transient receptor potential cation channel subfamily V member 1 Homo sapiens 25-30 26719417-0 2016 Understanding TRPV1 activation by ligands: Insights from the binding modes of capsaicin and resiniferatoxin. resiniferatoxin 92-107 transient receptor potential cation channel subfamily V member 1 Homo sapiens 14-19 26719417-4 2016 The recent cryo-electron microscopy structure of TRPV1 only provides a coarse characterization of the location of capsaicin (CAPS) and resiniferatoxin (RTX). resiniferatoxin 135-150 transient receptor potential cation channel subfamily V member 1 Homo sapiens 49-54 26719417-4 2016 The recent cryo-electron microscopy structure of TRPV1 only provides a coarse characterization of the location of capsaicin (CAPS) and resiniferatoxin (RTX). resiniferatoxin 152-155 transient receptor potential cation channel subfamily V member 1 Homo sapiens 49-54 26884754-3 2016 TRPV1 receptors function as homotetramers that also respond to heat, proinflammatory substances, lipoxygenase products, resiniferatoxin, endocannabinoids, protons, and peptide toxins. resiniferatoxin 120-135 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 25568328-4 2015 Using resiniferatoxin (RTX) as the agonist, we identified multiple gain-of-function substitutions within the TRPV1 pore turret (N628P and S629A), pore helix (F638A), and selectivity filter (M644A) domains. resiniferatoxin 6-21 transient receptor potential cation channel subfamily V member 1 Homo sapiens 109-114 25568328-4 2015 Using resiniferatoxin (RTX) as the agonist, we identified multiple gain-of-function substitutions within the TRPV1 pore turret (N628P and S629A), pore helix (F638A), and selectivity filter (M644A) domains. resiniferatoxin 23-26 transient receptor potential cation channel subfamily V member 1 Homo sapiens 109-114 24321344-0 2014 Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands. resiniferatoxin 64-79 transient receptor potential cation channel subfamily V member 1 Homo sapiens 100-140 24838827-5 2014 In contrast, treatment with the TRPV1-specific agonists, capsaicin (CAP) or resiniferatoxin (RTX) produced only a slight acceleration over a range of concentrations. resiniferatoxin 76-91 transient receptor potential cation channel subfamily V member 1 Homo sapiens 32-37 24838827-5 2014 In contrast, treatment with the TRPV1-specific agonists, capsaicin (CAP) or resiniferatoxin (RTX) produced only a slight acceleration over a range of concentrations. resiniferatoxin 93-96 transient receptor potential cation channel subfamily V member 1 Homo sapiens 32-37 26411767-8 2015 Thus activation of TRPV1 by oxidative stress, resiniferatoxin, cannabinoid receptor (CB1) activators (i.e. anandamide) or capsaicin induced epileptic effects, and these effects could be reduced by appropriate inhibitors, including capsazepine (CPZ), 5"-iodoresiniferatoxin (IRTX), resolvins, and CB1 antagonists. resiniferatoxin 46-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 19-24 25077949-5 2014 We demonstrate here that resiniferatoxin ablation of TRPV1 expressing neurons significantly reduces meningeal blood flow responses to nasal administration of both TRPV1 and TRPA1 agonists. resiniferatoxin 25-40 transient receptor potential cation channel subfamily V member 1 Homo sapiens 53-58 25077949-5 2014 We demonstrate here that resiniferatoxin ablation of TRPV1 expressing neurons significantly reduces meningeal blood flow responses to nasal administration of both TRPV1 and TRPA1 agonists. resiniferatoxin 25-40 transient receptor potential cation channel subfamily V member 1 Homo sapiens 163-168 25077949-6 2014 Accordingly resiniferatoxin also significantly reduces TRPV1 and CGRP immunostaining and TRPV1 and TRPA1 message levels in trigeminal ganglia. resiniferatoxin 12-27 transient receptor potential cation channel subfamily V member 1 Homo sapiens 55-60 25077949-6 2014 Accordingly resiniferatoxin also significantly reduces TRPV1 and CGRP immunostaining and TRPV1 and TRPA1 message levels in trigeminal ganglia. resiniferatoxin 12-27 transient receptor potential cation channel subfamily V member 1 Homo sapiens 89-94 24794110-0 2014 alpha-Methylated simplified resiniferatoxin (sRTX) thiourea analogues as potent and stereospecific TRPV1 antagonists. resiniferatoxin 28-43 transient receptor potential cation channel subfamily V member 1 Homo sapiens 99-104 24321344-0 2014 Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands. resiniferatoxin 64-79 transient receptor potential cation channel subfamily V member 1 Homo sapiens 142-147 21620567-4 2011 Desensitization of TRPV1-positive fibers with systemic resiniferatoxin (RTX) abolished spinal nerve ligation (SNL) injury-induced thermal hypersensitivity and spontaneous pain, but had no effect on tactile hypersensitivity. resiniferatoxin 55-70 transient receptor potential cation channel subfamily V member 1 Homo sapiens 19-24 23468922-4 2013 We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively. resiniferatoxin 114-129 transient receptor potential cation channel subfamily V member 1 Homo sapiens 84-89 23468922-4 2013 We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively. resiniferatoxin 114-129 transient receptor potential cation channel subfamily V member 1 Homo sapiens 236-241 23468922-4 2013 We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively. resiniferatoxin 131-134 transient receptor potential cation channel subfamily V member 1 Homo sapiens 84-89 23468922-4 2013 We found in various non-cancerous and cancerous mammalian epithelial cells that the TRPV1 agonists, capsaicin and resiniferatoxin (RTX), upregulated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70 and Hsp90 respectively, while the TRPV1 antagonists, capsazepine and AMG-9810, attenuated the accumulation of Hsp70, Hsp90 and Hsp27 and Hsp70, Hsp90, respectively. resiniferatoxin 131-134 transient receptor potential cation channel subfamily V member 1 Homo sapiens 236-241 22493457-1 2012 TRPV1 receptor agonists such as the vanilloid capsaicin and the potent analog resiniferatoxin are well known potent analgesics. resiniferatoxin 78-93 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 22262838-6 2012 After stimulation with resiniferatoxin, TRPV1 dimers tetramerize. resiniferatoxin 23-38 transient receptor potential cation channel subfamily V member 1 Homo sapiens 40-45 23352977-5 2013 TRPV1 antagonist capsazepine did not affect the capsaicin activity, and powerful TRPV1 agonist resiniferatoxin had no effect on CAPs, indicating no involvement of TRPV1 channels. resiniferatoxin 95-110 transient receptor potential cation channel subfamily V member 1 Homo sapiens 81-86 23352977-5 2013 TRPV1 antagonist capsazepine did not affect the capsaicin activity, and powerful TRPV1 agonist resiniferatoxin had no effect on CAPs, indicating no involvement of TRPV1 channels. resiniferatoxin 95-110 transient receptor potential cation channel subfamily V member 1 Homo sapiens 81-86 23139219-13 2013 Conversely capsaicin, resiniferatoxin, and N-oleoyldopamine raised intracellular calcium ([Ca(2+)](i)) in T84 cells and AMG-9810 blocked the rise in [Ca(2+)](i) induced by capsaicin and resiniferatoxin suggesting the presence of a functional TRPV1 channel. resiniferatoxin 22-37 transient receptor potential cation channel subfamily V member 1 Homo sapiens 242-247 26779292-2 2013 Like capsaicin, RTX is a vanilloid receptor (TRPV1) agonist, only more potent. resiniferatoxin 16-19 transient receptor potential cation channel subfamily V member 1 Homo sapiens 45-50 21620567-4 2011 Desensitization of TRPV1-positive fibers with systemic resiniferatoxin (RTX) abolished spinal nerve ligation (SNL) injury-induced thermal hypersensitivity and spontaneous pain, but had no effect on tactile hypersensitivity. resiniferatoxin 72-75 transient receptor potential cation channel subfamily V member 1 Homo sapiens 19-24 20884761-6 2010 Bath application of 2AG or the TRPV1 agonists capsaicin and resiniferatoxin mimicked LTD and both capsaicin- and 2AG-induced depression were blocked by capsazepine. resiniferatoxin 60-75 transient receptor potential cation channel subfamily V member 1 Homo sapiens 31-36 21671878-0 2011 Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials. resiniferatoxin 34-49 transient receptor potential cation channel subfamily V member 1 Homo sapiens 25-30 21671878-4 2011 This has rekindled interest in desensitization of nociceptive neurons to TRPV1 agonists (e.g. capsaicin and its ultrapotent analog resiniferatoxin) as an alternative pharmacological approach to block pain in the periphery where it is generated. resiniferatoxin 131-146 transient receptor potential cation channel subfamily V member 1 Homo sapiens 73-78 21671879-2 2011 The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation. resiniferatoxin 22-37 transient receptor potential cation channel subfamily V member 1 Homo sapiens 113-118 21671879-2 2011 The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation. resiniferatoxin 22-37 transient receptor potential cation channel subfamily V member 1 Homo sapiens 228-233 21237298-4 2011 We report that in osteoclasts from osteoporotic patients, TRPV1 channels are upregulated and, if persistently stimulated with resiniferatoxin, become clustered to the plasma membrane while inducing a massive over-expression of CB2 receptors. resiniferatoxin 126-141 transient receptor potential cation channel subfamily V member 1 Homo sapiens 58-63 21276877-6 2011 The TRPV1 agonist, resiniferatoxin (0.65-1.0mM/L in 100nL), prolonged the LCR after bilateral injection into the NTS even when the body temperature of each piglet was normal. resiniferatoxin 19-34 transient receptor potential cation channel subfamily V member 1 Homo sapiens 4-9 19695100-3 2009 RESULTS: Fluorescent imaging of Fura-2 loaded human SW982 synoviocytes reveals immediate and delayed cytosolic calcium oscillations elicited by (1) TRPV1 agonists capsaicin and resiniferatoxin (20-40% of cells), (2) moderate and noxious temperature change, and (3) osmotic stress TRPV4 activation (11.5% of cells). resiniferatoxin 177-192 transient receptor potential cation channel subfamily V member 1 Homo sapiens 148-153 20230457-9 2010 Clinical use of resiniferatoxin, another ancient but potent TRPV1 agonist, is also being explored as a therapy for refractory pain. resiniferatoxin 16-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 60-65 20501335-3 2010 Inflammation was induced by intracolonic instillation of trinitrobenzene sulfonic acid (TNBS, 12.5mg/kg), and desensitization of TRPV1 receptors was evoked by intracolonic resiniferatoxin (RTX, 10(-)(7)M). resiniferatoxin 172-187 transient receptor potential cation channel subfamily V member 1 Homo sapiens 129-134 20501335-3 2010 Inflammation was induced by intracolonic instillation of trinitrobenzene sulfonic acid (TNBS, 12.5mg/kg), and desensitization of TRPV1 receptors was evoked by intracolonic resiniferatoxin (RTX, 10(-)(7)M). resiniferatoxin 189-192 transient receptor potential cation channel subfamily V member 1 Homo sapiens 129-134 19275664-4 2009 Initially, the focus was on the development of TRPV1 agonists e.g. capsaicin and resiniferatoxin (RTX) as analgesic agents through the desensitization/denervation approach. resiniferatoxin 81-96 transient receptor potential cation channel subfamily V member 1 Homo sapiens 47-52 19294370-2 2009 TRPV1 receptors can be activated by noxious heat, acid, capsaicin and resiniferatoxin, leading to burning pain or itch mediated by discharges in C polymodal and Adelta mechano-heat nociceptors and in central neurons, including spinothalamic tract (STT) cells. resiniferatoxin 70-85 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 19059369-5 2009 Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers. resiniferatoxin 66-81 transient receptor potential cation channel subfamily V member 1 Homo sapiens 101-106 19059369-5 2009 Consistently, biomolecular and functional experiments showed that resiniferatoxin (RTX), a selective TRPV1 receptor agonist, increased the expression and the activity of TRAP and cathepsin K, two specific osteoclast biomarkers. resiniferatoxin 83-86 transient receptor potential cation channel subfamily V member 1 Homo sapiens 101-106 19275664-4 2009 Initially, the focus was on the development of TRPV1 agonists e.g. capsaicin and resiniferatoxin (RTX) as analgesic agents through the desensitization/denervation approach. resiniferatoxin 98-101 transient receptor potential cation channel subfamily V member 1 Homo sapiens 47-52 18199335-1 2008 Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that binds to the transient receptor potential channel, vanilloid subfamily member 1 (TRPV1). resiniferatoxin 0-15 transient receptor potential cation channel subfamily V member 1 Homo sapiens 143-148 18199335-1 2008 Resiniferatoxin (RTX) is an ultrapotent capsaicin analog that binds to the transient receptor potential channel, vanilloid subfamily member 1 (TRPV1). resiniferatoxin 17-20 transient receptor potential cation channel subfamily V member 1 Homo sapiens 143-148 18199335-8 2008 Recovery studies showed that physiologic sensory function could return as early as two weeks post-RTX treatment, however, immunohistochemical examination of the DRG revealed a partial, but significant reduction in the number of the TRPV1-positive neurons. resiniferatoxin 98-101 transient receptor potential cation channel subfamily V member 1 Homo sapiens 232-237 17705161-2 2007 RTX, a capsaicin analogue devoid of severe pungent properties, acts by desensitizing the transient receptor potential vanilloid type 1 (TRPV1) receptor and inactivating C-fibers. resiniferatoxin 0-3 transient receptor potential cation channel subfamily V member 1 Homo sapiens 89-134 17711510-0 2007 Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. resiniferatoxin 145-160 transient receptor potential cation channel subfamily V member 1 Homo sapiens 24-74 17711510-10 2007 Transcript levels before treatment correlated significantly with the therapeutic effect of resiniferatoxin (P = 0.004), with higher TRPV1 mRNA expression in responders (median 1.50, range 0.89-2.78) than nonresponders (0.74, 0.34-1.32). resiniferatoxin 91-106 transient receptor potential cation channel subfamily V member 1 Homo sapiens 132-137 17711510-12 2007 CONCLUSION: Successful intravesical resiniferatoxin treatment is closely associated with the over-expression of TRPV1 in the bladder mucosa and submucosa in patients with IDO. resiniferatoxin 36-51 transient receptor potential cation channel subfamily V member 1 Homo sapiens 112-117 18852901-11 2008 CONCLUSION: TRPV1B expression, together with low TRPV1 expression, may explain the vanilloid paradox: even genuinely TRPV1 mRNA positive cells can be spared with therapeutic (up to micromolar) doses of RTX. resiniferatoxin 202-205 transient receptor potential cation channel subfamily V member 1 Homo sapiens 12-17 17705161-2 2007 RTX, a capsaicin analogue devoid of severe pungent properties, acts by desensitizing the transient receptor potential vanilloid type 1 (TRPV1) receptor and inactivating C-fibers. resiniferatoxin 0-3 transient receptor potential cation channel subfamily V member 1 Homo sapiens 136-141 15913603-3 2005 The kinetic parameters inferred from [(125)I]-resiniferatoxin binding were in concordance with data of TRPV1 receptors expressed in other tissues. resiniferatoxin 46-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 103-108 17442052-6 2007 Capsaicin, anandamide, resiniferatoxin and olvanil mediated increases in [Ca(2+)](i) were inhibited by the TRPV1 antagonists capsazepine and iodo-resiniferatoxin with potencies (K(B)) of approximately 70 nmol/L and 2 nmol/L, respectively. resiniferatoxin 23-38 transient receptor potential cation channel subfamily V member 1 Homo sapiens 107-112 16091583-9 2006 Upon heterologous expression in HEK 293 cells, TRPV1(VAR) potentiated the ability of cotransfected TRPV1 to confer calcium influx in response to resiniferatoxin. resiniferatoxin 145-160 transient receptor potential cation channel subfamily V member 1 Homo sapiens 47-52 16091583-9 2006 Upon heterologous expression in HEK 293 cells, TRPV1(VAR) potentiated the ability of cotransfected TRPV1 to confer calcium influx in response to resiniferatoxin. resiniferatoxin 145-160 transient receptor potential cation channel subfamily V member 1 Homo sapiens 99-104 16288992-5 2005 The various TRPV1 agonists activated pTRPV1 in a dose-dependent manner in the order of potency of resiniferatoxin (RTX) > olvanil > capsaicin > phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV), phorbol 12,13-dinonanoate 20-homovanillate (PDNHV). resiniferatoxin 98-113 transient receptor potential cation channel subfamily V member 1 Homo sapiens 12-17 16288992-5 2005 The various TRPV1 agonists activated pTRPV1 in a dose-dependent manner in the order of potency of resiniferatoxin (RTX) > olvanil > capsaicin > phorbol 12-phenylacetate 13-acetate 20-homovanillate (PPAHV), phorbol 12,13-dinonanoate 20-homovanillate (PDNHV). resiniferatoxin 115-118 transient receptor potential cation channel subfamily V member 1 Homo sapiens 12-17 17540346-7 2007 Resiniferatoxin (RTX; 2 microg/ml, 100 microl), an ultra potent analog of capsaicin, was injected locally into the left hindpaw to functionally inactivate TRPV-1 containing sensory terminals. resiniferatoxin 0-15 transient receptor potential cation channel subfamily V member 1 Homo sapiens 155-161 17214968-5 2007 These data support the hypothesis that (E)-capsaicin, resiniferatoxin, capsazepine, and SB366791 are all mitochondrial inhibitors, able to activate apoptosis and/or necrosis via non-receptor mediated mechanisms, and also support the use of TRPV1 ligands as anti-cancer agents. resiniferatoxin 54-69 transient receptor potential cation channel subfamily V member 1 Homo sapiens 240-245 16597917-3 2006 As shown by fura-2 ratio measurements while cells were incubated in a temperature-regulated chamber, significant [Ca(2+)](cyt) elevation was elicited by rapid changes in bath temperature, application of TRPV1 receptor agonists capsaicin and resiniferatoxin, or a cold receptor stimulator, icilin. resiniferatoxin 241-256 transient receptor potential cation channel subfamily V member 1 Homo sapiens 203-208 16627674-3 2006 Irritant agents, including capsaicin, resiniferatoxin, and citric acid, elicit cough in humans and in experimental animals through the activation of the transient receptor potential vanilloid 1 (TRPV1). resiniferatoxin 38-53 transient receptor potential cation channel subfamily V member 1 Homo sapiens 153-193 16627674-3 2006 Irritant agents, including capsaicin, resiniferatoxin, and citric acid, elicit cough in humans and in experimental animals through the activation of the transient receptor potential vanilloid 1 (TRPV1). resiniferatoxin 38-53 transient receptor potential cation channel subfamily V member 1 Homo sapiens 195-200 15936040-1 2005 After 7 years from its cloning, the transient receptor potential vanilloid type-1 (TRPV1) channel remains the sole membrane receptor mediating the pharmacological effects of the hot chilli pepper pungent component, capsaicin, and of the Euphorbia toxin, resiniferatoxin. resiniferatoxin 254-269 transient receptor potential cation channel subfamily V member 1 Homo sapiens 36-81 15936040-1 2005 After 7 years from its cloning, the transient receptor potential vanilloid type-1 (TRPV1) channel remains the sole membrane receptor mediating the pharmacological effects of the hot chilli pepper pungent component, capsaicin, and of the Euphorbia toxin, resiniferatoxin. resiniferatoxin 254-269 transient receptor potential cation channel subfamily V member 1 Homo sapiens 83-88 15913603-5 2005 Addition of capsaicin, (R)-methanandamide and resiniferatoxin to prostate cells induced a dose-dependent increase in the intracellular calcium concentration that was reversed by the vanilloid TRPV1 receptor antagonist capsazepine. resiniferatoxin 46-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 192-197 15708075-1 2005 OBJECTIVES: To study TRPV1 immunoreactivity in the urothelium of patients with neurogenic detrusor overactivity (NDO) before and after treatment with resiniferatoxin (RTX) and controls. resiniferatoxin 150-165 transient receptor potential cation channel subfamily V member 1 Homo sapiens 21-26 15918513-1 2005 A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants. resiniferatoxin 120-135 transient receptor potential cation channel subfamily V member 1 Homo sapiens 22-25 15918513-1 2005 A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants. resiniferatoxin 120-135 transient receptor potential cation channel subfamily V member 1 Homo sapiens 40-45 15918513-1 2005 A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants. resiniferatoxin 137-140 transient receptor potential cation channel subfamily V member 1 Homo sapiens 22-25 15918513-1 2005 A vanilloid receptor (VR1, now known as TRPV1) is an ion channel activated by vanilloids, including capsaicin (CAP) and resiniferatoxin (RTX), which are pungent ingredients of plants. resiniferatoxin 137-140 transient receptor potential cation channel subfamily V member 1 Homo sapiens 40-45 15708075-3 2005 In patients with NDO, TRPV1 suburothelial nerve density is increased, which is reversed by successful treatment with intravesical RTX. resiniferatoxin 130-133 transient receptor potential cation channel subfamily V member 1 Homo sapiens 22-27 15708075-9 2005 In 5 patients who responded clinically to RTX, basal cell layer and total urothelial TRPV1 immunoreactivity decreased significantly after treatment (P = 0.032 and P = 0.016, respectively). resiniferatoxin 42-45 transient receptor potential cation channel subfamily V member 1 Homo sapiens 85-90 14637384-3 2003 RTX application to DRG cells identified as type 1, 2 or 5, cell types known to express VR1, induced large inward currents. resiniferatoxin 0-3 transient receptor potential cation channel subfamily V member 1 Homo sapiens 87-90 15579007-3 2004 Small molecule agonists of VR1, including capsaicin and RTX, are currently utilized for a number of clinical syndromes, including intractable neuropathic pain, spinal detrusor hyperreflexia, and bladder hypersensitivity; however, antagonists of VR1 have yet to reach the clinic. resiniferatoxin 56-59 transient receptor potential cation channel subfamily V member 1 Homo sapiens 245-248 15548449-11 2004 CONCLUSION: The present findings provide the evidence of the presence of TRPV1 on normal human urothelium where it could have important implications in the mechanism of action of intravesical vanilloids (capsaicin and resiniferatoxin). resiniferatoxin 218-233 transient receptor potential cation channel subfamily V member 1 Homo sapiens 73-78 14996838-1 2004 Vanilloid receptor 1 (TRPV1), a membrane-associated cation channel, is activated by the pungent vanilloid from chili peppers, capsaicin, and the ultra potent vanilloid from Euphorbia resinifera, resiniferatoxin (RTX), as well as by physical stimuli (heat and protons) and proposed endogenous ligands (anandamide, N-arachidonyldopamine, N-oleoyldopamine, and products of lipoxygenase). resiniferatoxin 195-210 transient receptor potential cation channel subfamily V member 1 Homo sapiens 22-27 14996838-1 2004 Vanilloid receptor 1 (TRPV1), a membrane-associated cation channel, is activated by the pungent vanilloid from chili peppers, capsaicin, and the ultra potent vanilloid from Euphorbia resinifera, resiniferatoxin (RTX), as well as by physical stimuli (heat and protons) and proposed endogenous ligands (anandamide, N-arachidonyldopamine, N-oleoyldopamine, and products of lipoxygenase). resiniferatoxin 212-215 transient receptor potential cation channel subfamily V member 1 Homo sapiens 22-27 14996838-9 2004 Based on our data we propose a model of the TM3/4 region of TRPV1 bound to capsaicin or RTX that may aid in the development of potent TRPV1 antagonists with utility in the treatment of sensory disorders. resiniferatoxin 88-91 transient receptor potential cation channel subfamily V member 1 Homo sapiens 60-65 14996838-9 2004 Based on our data we propose a model of the TM3/4 region of TRPV1 bound to capsaicin or RTX that may aid in the development of potent TRPV1 antagonists with utility in the treatment of sensory disorders. resiniferatoxin 88-91 transient receptor potential cation channel subfamily V member 1 Homo sapiens 134-139 14992587-0 2004 Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain. resiniferatoxin 0-15 transient receptor potential cation channel subfamily V member 1 Homo sapiens 29-47 14992587-0 2004 Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain. resiniferatoxin 0-15 transient receptor potential cation channel subfamily V member 1 Homo sapiens 49-54 16173059-3 2005 TRPV1 antagonists and reduction of calcium concentrations in treatment solutions attenuated calcium flux, induction of interleukin-6 and 8 gene expression, and IL-6 secretion by cells treated with capsaicin or resiniferatoxin. resiniferatoxin 210-225 transient receptor potential cation channel subfamily V member 1 Homo sapiens 0-5 15579007-3 2004 Small molecule agonists of VR1, including capsaicin and RTX, are currently utilized for a number of clinical syndromes, including intractable neuropathic pain, spinal detrusor hyperreflexia, and bladder hypersensitivity; however, antagonists of VR1 have yet to reach the clinic. resiniferatoxin 56-59 transient receptor potential cation channel subfamily V member 1 Homo sapiens 27-30 15124026-4 2004 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons. resiniferatoxin 43-58 transient receptor potential cation channel subfamily V member 1 Homo sapiens 29-34 15124026-4 2004 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons. resiniferatoxin 43-58 transient receptor potential cation channel subfamily V member 1 Homo sapiens 131-136 15124026-4 2004 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons. resiniferatoxin 60-63 transient receptor potential cation channel subfamily V member 1 Homo sapiens 29-34 15124026-4 2004 Administration of the potent TRPV1 agonist resiniferatoxin (RTX) to neuronal perikarya induces calcium cytotoxicity by opening the TRPV1 ion channel and selectively ablates nociceptive neurons. resiniferatoxin 60-63 transient receptor potential cation channel subfamily V member 1 Homo sapiens 131-136 15049988-13 2004 CONCLUSIONS: The decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres in responders to resiniferatoxin (to levels in control tissues) suggests that the increased numbers of nerve fibres in patients with NDO are mainly of sensory origin and express TRPV1. resiniferatoxin 91-106 transient receptor potential cation channel subfamily V member 1 Homo sapiens 40-45 15049988-13 2004 CONCLUSIONS: The decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres in responders to resiniferatoxin (to levels in control tissues) suggests that the increased numbers of nerve fibres in patients with NDO are mainly of sensory origin and express TRPV1. resiniferatoxin 91-106 transient receptor potential cation channel subfamily V member 1 Homo sapiens 252-257 12522087-0 2003 Activation of vanilloid receptor 1 by resiniferatoxin mobilizes calcium from inositol 1,4,5-trisphosphate-sensitive stores. resiniferatoxin 38-53 transient receptor potential cation channel subfamily V member 1 Homo sapiens 14-34 12608892-2 2003 Stimulation of TRPV1-expressing cells, but not control Sf 9 cells, with resiniferatoxin (RTX), capsaicin or anandamide, produced an increase in cytosolic free Ca(2+) concentration ([Ca(2+)](i)), with EC(50) values of 166 pM, 24.5 nM and 3.89 microM respectively. resiniferatoxin 72-87 transient receptor potential cation channel subfamily V member 1 Homo sapiens 15-20 12608892-2 2003 Stimulation of TRPV1-expressing cells, but not control Sf 9 cells, with resiniferatoxin (RTX), capsaicin or anandamide, produced an increase in cytosolic free Ca(2+) concentration ([Ca(2+)](i)), with EC(50) values of 166 pM, 24.5 nM and 3.89 microM respectively. resiniferatoxin 89-92 transient receptor potential cation channel subfamily V member 1 Homo sapiens 15-20 12522087-9 2003 We conclude that VR1 is able to couple to Ca2+ mobilization by a Ca2+ dependent mechanism, mediated by capsaicin and RTX, and a Ca2+ independent mechanism mediated by RTX alone. resiniferatoxin 117-120 transient receptor potential cation channel subfamily V member 1 Homo sapiens 17-20 12522087-9 2003 We conclude that VR1 is able to couple to Ca2+ mobilization by a Ca2+ dependent mechanism, mediated by capsaicin and RTX, and a Ca2+ independent mechanism mediated by RTX alone. resiniferatoxin 167-170 transient receptor potential cation channel subfamily V member 1 Homo sapiens 17-20 12922928-2 2003 The C-5 halogenation of the vanillyl moiety of resiniferatoxin, an ultrapotent agonist of vanilloid TRPV1 receptors, results in a potent antagonist for these receptors. resiniferatoxin 47-62 transient receptor potential cation channel subfamily V member 1 Homo sapiens 100-105 12522087-1 2003 1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones. resiniferatoxin 16-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 74-94 12522087-1 2003 1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones. resiniferatoxin 16-31 transient receptor potential cation channel subfamily V member 1 Homo sapiens 96-99 12522087-1 2003 1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones. resiniferatoxin 33-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 74-94 12522087-1 2003 1 Capsaicin and resiniferatoxin (RTX) stimulate Ca2+ influx by activating vanilloid receptor 1 (VR1), a ligand-gated Ca2+ channel on sensory neurones. resiniferatoxin 33-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 96-99 12522087-4 2003 3 In Ca2+ -free media, RTX caused a transient elevation in intracellular free Ca2+ concentration in hVR1-HEK293 cells (pEC(50) 6.45+/-0.05) but not in wild type cells. resiniferatoxin 23-26 transient receptor potential cation channel subfamily V member 1 Homo sapiens 100-104 12522087-7 2003 These data suggest that RTX causes Ca2+ mobilization from inositol 1,4,5-trisphosphate-sensitive Ca2+ stores in hVR1-HEK293 cells. resiniferatoxin 24-27 transient receptor potential cation channel subfamily V member 1 Homo sapiens 112-116 12007523-1 2002 Very recently, a membrane receptor (vanilloid receptor type 1 [VR-1]) sensitive to capsaicin or resiniferatoxin (RTX) was identified in small- and medium-sized dorsal root ganglion neurons that give rise to most unmyelinated sensory fibers. resiniferatoxin 96-111 transient receptor potential cation channel subfamily V member 1 Homo sapiens 63-67 12438527-1 2002 We have synthesized iodinated resiniferatoxin bearing a 4-hydroxy-5-iodo-3-methoxyphenylacetate ester (I-RTX) and have characterized its activity on rat and human TRPV1 (VR1) receptors, as well as in behavioral assays of nociception. resiniferatoxin 30-45 transient receptor potential cation channel subfamily V member 1 Homo sapiens 163-168 12438527-1 2002 We have synthesized iodinated resiniferatoxin bearing a 4-hydroxy-5-iodo-3-methoxyphenylacetate ester (I-RTX) and have characterized its activity on rat and human TRPV1 (VR1) receptors, as well as in behavioral assays of nociception. resiniferatoxin 30-45 transient receptor potential cation channel subfamily V member 1 Homo sapiens 170-173 14599363-9 2002 For both rVR1 and hVR1, time-response waveforms elicited by resiniferatoxin increased more gradually compared to other agonists. resiniferatoxin 60-75 transient receptor potential cation channel subfamily V member 1 Homo sapiens 18-22 12007523-1 2002 Very recently, a membrane receptor (vanilloid receptor type 1 [VR-1]) sensitive to capsaicin or resiniferatoxin (RTX) was identified in small- and medium-sized dorsal root ganglion neurons that give rise to most unmyelinated sensory fibers. resiniferatoxin 113-116 transient receptor potential cation channel subfamily V member 1 Homo sapiens 63-67 11834295-1 2002 Specific [3H]resiniferatoxin (RTX) binding detects the vanilloid receptor type I (VR1). resiniferatoxin 13-28 transient receptor potential cation channel subfamily V member 1 Homo sapiens 55-85 11934585-0 2002 Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor. resiniferatoxin 55-70 transient receptor potential cation channel subfamily V member 1 Homo sapiens 124-127 11834295-1 2002 Specific [3H]resiniferatoxin (RTX) binding detects the vanilloid receptor type I (VR1). resiniferatoxin 30-33 transient receptor potential cation channel subfamily V member 1 Homo sapiens 55-85 11752091-6 2002 The data demonstrate that VR1 receptor agonists capsaicin and resiniferatoxin lead to a sustained increase in intracellular calcium and sodium in a concentration-dependent manner, followed by cell death. resiniferatoxin 62-77 transient receptor potential cation channel subfamily V member 1 Homo sapiens 26-29 34421597-10 2021 This statement is mainly derived from our studies with resiniferatoxin (RTX) a potent TRPV1 agonist but also from protein therapeutics using a conjugate of Substance P and saporin. resiniferatoxin 55-70 transient receptor potential cation channel subfamily V member 1 Homo sapiens 86-91 11587243-8 2001 The potent VR1 agonist resiniferatoxin, now in phase II clinical trials, appears to be superior to capsaicin in terms of its tolerability profile. resiniferatoxin 23-38 transient receptor potential cation channel subfamily V member 1 Homo sapiens 11-14 8057776-0 1994 [3H]resiniferatoxin binding by the human vanilloid (capsaicin) receptor. resiniferatoxin 4-19 transient receptor potential cation channel subfamily V member 1 Homo sapiens 41-71 8057776-2 1994 Specific [3H]resiniferatoxin (RTX) binding is thought to represent the vanilloid (capsaicin) receptor. resiniferatoxin 13-28 transient receptor potential cation channel subfamily V member 1 Homo sapiens 71-101 8057776-2 1994 Specific [3H]resiniferatoxin (RTX) binding is thought to represent the vanilloid (capsaicin) receptor. resiniferatoxin 30-33 transient receptor potential cation channel subfamily V member 1 Homo sapiens 71-101 11124944-3 2001 Upon exposure to resiniferatoxin, VR1eGFP- or VR1epsilon-expressing cells exhibited pharmacological responses similar to those of cells expressing the untagged VR1. resiniferatoxin 17-32 transient receptor potential cation channel subfamily V member 1 Homo sapiens 34-49 11124944-3 2001 Upon exposure to resiniferatoxin, VR1eGFP- or VR1epsilon-expressing cells exhibited pharmacological responses similar to those of cells expressing the untagged VR1. resiniferatoxin 17-32 transient receptor potential cation channel subfamily V member 1 Homo sapiens 34-37 11124944-7 2001 Nociceptive primary sensory neurons endogenously express VR1, and resiniferatoxin treatment induced a sudden increase in [Ca(2+)](i) and mitochondrial disruption which was cell-selective, as glia and non-VR1-expressing neurons were unaffected. resiniferatoxin 66-81 transient receptor potential cation channel subfamily V member 1 Homo sapiens 204-207 11166956-6 2001 In contrast, resiniferatoxin and its analog, phorbol 12-phenylacetate 13-acetate 20-homovanillate, was more potent in activating the CAP-activated channels in cultured sensory neurons than VR1. resiniferatoxin 13-28 transient receptor potential cation channel subfamily V member 1 Homo sapiens 189-192 10903936-1 2000 BACKGROUND: Vanilloids, such as capsaicin and resiniferatoxin (RTX), are recognized at the cell surface by vanilloid receptor type 1 (VR1), which has recently been cloned. resiniferatoxin 46-61 transient receptor potential cation channel subfamily V member 1 Homo sapiens 107-137 10903936-1 2000 BACKGROUND: Vanilloids, such as capsaicin and resiniferatoxin (RTX), are recognized at the cell surface by vanilloid receptor type 1 (VR1), which has recently been cloned. resiniferatoxin 63-66 transient receptor potential cation channel subfamily V member 1 Homo sapiens 107-137 17038971-3 1998 In spite of this, ultrapotent capsaicin analogues such as resiniferatoxin, which also interact with the vanilloid receptor subtype 1, are being studied. resiniferatoxin 58-73 transient receptor potential cation channel subfamily V member 1 Homo sapiens 104-132 8015709-0 1994 Characterization by [3H]resiniferatoxin binding of a human vanilloid (capsaicin) receptor in post-mortem spinal cord. resiniferatoxin 24-39 transient receptor potential cation channel subfamily V member 1 Homo sapiens 59-89 34504955-1 2021 Both a silent resident phosphatidylinositol lipid and a "hot" vanilloid agonist capsaicin or resiniferatoxin have been shown to share the same inter-subunit binding pocket between a voltage sensor like domain and a pore domain in TRPV1. resiniferatoxin 93-108 transient receptor potential cation channel subfamily V member 1 Homo sapiens 230-235 34421597-10 2021 This statement is mainly derived from our studies with resiniferatoxin (RTX) a potent TRPV1 agonist but also from protein therapeutics using a conjugate of Substance P and saporin. resiniferatoxin 72-75 transient receptor potential cation channel subfamily V member 1 Homo sapiens 86-91 35610228-2 2022 Here, we use thermal titration methods and cryo-EM in an attempt to obtain temporal resolution of the conformational trajectory of the vanilloid receptor TRPV1 with resiniferatoxin (RTx) bound. resiniferatoxin 165-180 transient receptor potential cation channel subfamily V member 1 Homo sapiens 154-159 35610228-2 2022 Here, we use thermal titration methods and cryo-EM in an attempt to obtain temporal resolution of the conformational trajectory of the vanilloid receptor TRPV1 with resiniferatoxin (RTx) bound. resiniferatoxin 182-185 transient receptor potential cation channel subfamily V member 1 Homo sapiens 154-159 35610228-5 2022 Greater understanding of the RTx-mediated long-range allostery of TRPV1 could help further the therapeutic potential of RTx, which is a promising drug candidate for pain relief associated with advanced cancer or knee arthritis. resiniferatoxin 29-32 transient receptor potential cation channel subfamily V member 1 Homo sapiens 66-71 35610228-5 2022 Greater understanding of the RTx-mediated long-range allostery of TRPV1 could help further the therapeutic potential of RTx, which is a promising drug candidate for pain relief associated with advanced cancer or knee arthritis. resiniferatoxin 120-123 transient receptor potential cation channel subfamily V member 1 Homo sapiens 66-71 35350319-5 2022 We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation. resiniferatoxin 123-138 transient receptor potential cation channel subfamily V member 1 Homo sapiens 31-36 35350319-5 2022 We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation. resiniferatoxin 123-138 transient receptor potential cation channel subfamily V member 1 Homo sapiens 246-251 35350319-5 2022 We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation. resiniferatoxin 140-143 transient receptor potential cation channel subfamily V member 1 Homo sapiens 31-36 35350319-5 2022 We demonstrate that endogenous TRPV1 is functional and causes Ca2+ influx upon activation with pharmacological activators (resiniferatoxin (RTX) and capsaicin) at nanomolar concentration, which enhances the generation of osteoclasts, whereas the TRPV1 inhibitor (5"-IRTX) reduces osteoclast differentiation. resiniferatoxin 140-143 transient receptor potential cation channel subfamily V member 1 Homo sapiens 246-251 35350319-7 2022 The slow release of capsaicin or RTX at a nanomolar concentration from a polysaccharide-based hydrogel enhances bone marrow macrophage (BMM) differentiation into osteoclasts whereas release of 5"-IRTX, an inhibitor of TRPV1, prevents macrophage fusion and osteoclast formation. resiniferatoxin 33-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 218-223